Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
12.05.2026 05:00
Elecsys® pTau217 is the first blood test for Alzheimer’s disease pathology with a single‑assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world.1,2,5While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys® pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw.1,2,4,7,8,11Diagnosing d
Eli Lilly’s Omvoh Data Extends Ulcerative Colitis Story And Valuation Appeal
12.05.2026 00:17
Eli Lilly's Omvoh (mirikizumab) has shown durable disease clearance over four years in patients with moderately to severely active ulcerative colitis. The long term data adds to existing evidence on Omvoh's efficacy and safety in inflammatory bowel disease. The results reinforce Eli Lilly's position in immunology and provide new information for clinicians and patients considering chronic treatment options. Eli Lilly (NYSE:LLY) enters this update with Omvoh's four year results adding another...
Sanofi: Great Yield And Plenty Of Upside Potential
11.05.2026 11:08
Sanofi (SNY) stock: Strong Buy with 5.5%+ yield, undervalued multiples, and 16â20% projected returns from its robust pipelineâread the thesis here.
Eli Lilly and Company (NYSE:LLY) Looks Interesting, And It's About To Pay A Dividend
11.05.2026 10:43
Eli Lilly and Company ( NYSE:LLY ) is about to trade ex-dividend in the next 3 days. The ex-dividend date occurs one...
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen
11.05.2026 09:10
Eli Lilly (LLY) excels in the "Little Book That Makes You Rich" strategy, showing 47% revenue growth, 114% EPS growth, 81% ROE, and consistent earnings surprises, making it a top growth stock candidate.
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
11.05.2026 06:35
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.Builds toward the establishment of
Eli Lilly To Acquire Kelonia Therapeutics
11.05.2026 04:09
On April 20, 2026, Eli Lilly & Company and Kelonia Therapeutics, Inc. announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expected to close in the second half of 2026....
Trump Admin Proposes New IVF Benefit To Expand Fertility CoverageThrough Employers
11.05.2026 03:22
Trump administration proposes new IVF benefits rule aimed at expanding employer fertility coverage and lowering treatment costs.
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
09.05.2026 10:25
The weight loss drug market is on track to reach almost $100 billion.
GLP-1 battle heats up between Eli Lilly and Novo Nordisk
08.05.2026 15:42
BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).
New PatentVest Pulse Report Maps the Triple-Agonist Race and the Emerging Patent Battle Shaping the Post-GLP-1 Obesity Market
08.05.2026 14:30
· Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms. · PatentVest’s report reveals how intellectual property strategy, receptor-ratio engineering, and delivery platforms may determine the next leaders in obesity therapeutics. DALLAS, TX, May 08, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, “The T
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
08.05.2026 13:50
The competition is far behind.
Omada Health Q1 Earnings Call Highlights
08.05.2026 12:07
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off
08.05.2026 12:00
Eli Lilly is just wrapping up trials of its retatrutide, but consumers already are flocking to black-market versions. Can Lilly compete with copies of its own drug?
Lilly to invest extra $4.5B across Indiana manufacturing
08.05.2026 11:33
The Indianapolis-based company expanded its spend to ensure it can meet growing demand for genetic therapies and weight-loss drugs.
Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years
08.05.2026 11:16
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. The offering, which initially targeted $8 billion, saw high investor demand following […]
Eli Lilly's (NYSE:LLY) Earnings Are Weaker Than They Seem
08.05.2026 10:19
Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. We did some...
Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific Advisor
08.05.2026 09:01
The recruitment represents a significant strategic addition to the company as it continues the development of its innovative drug platform within pain and inflammatory diseases. Dr. Lundberg has had a long and highly successful international career spanning both academia and the global pharmaceutical industry. He began his career as a researcher and professor at the Karolinska Institute and established himself at a very early stage as one of the world's 100 most cited scientists.
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake
08.05.2026 08:57
Eli Lilly's new oralweight-loss drug, Foundayo, was prescribed 7,335 times in theU.S. in the fourth week, a modest uptake compared to rival NovoNordisk's Wegovy pill, analysts said. ...
My Top Obesity Stock to Buy and Hold
07.05.2026 09:05
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.